CY1118044T1 - Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες - Google Patents

Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες

Info

Publication number
CY1118044T1
CY1118044T1 CY20161100983T CY161100983T CY1118044T1 CY 1118044 T1 CY1118044 T1 CY 1118044T1 CY 20161100983 T CY20161100983 T CY 20161100983T CY 161100983 T CY161100983 T CY 161100983T CY 1118044 T1 CY1118044 T1 CY 1118044T1
Authority
CY
Cyprus
Prior art keywords
competitor
corticosteroids
composition preparation
combination therapy
diseases
Prior art date
Application number
CY20161100983T
Other languages
English (en)
Inventor
Peter Wehling
Julio Reinecke
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of CY1118044T1 publication Critical patent/CY1118044T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Η παρούσα εφεύρεση σχετίζεται με φαρμακευτικές συνθέσεις για μία θεραπεία συνδυασμού, που περιλαμβάνει ένα ανταγωνιστή κυτοκίνης (cytokine) και ένα κορτικοστεροειδές. Η εν λόγω θεραπεία συνδυασμού επιτρέπει την θεραπεία ασθενειών όπως οστεοαρθρίτιδα, διαταραχές τενόντων και/ ή εκφυλιστικές ασθένειες της σπονδυλικής στήλης.
CY20161100983T 2009-12-10 2016-10-04 Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες CY1118044T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009057495 2009-12-10
PCT/EP2010/069427 WO2011082951A1 (de) 2009-12-10 2010-12-10 Kombinationspräparate mit cytokin-antagonist und corticosteroid

Publications (1)

Publication Number Publication Date
CY1118044T1 true CY1118044T1 (el) 2017-05-17

Family

ID=43707934

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100969T CY1118081T1 (el) 2009-12-10 2016-09-29 Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες
CY20161100983T CY1118044T1 (el) 2009-12-10 2016-10-04 Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100969T CY1118081T1 (el) 2009-12-10 2016-09-29 Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες

Country Status (22)

Country Link
US (3) US8828946B2 (el)
EP (2) EP2437748B8 (el)
JP (2) JP5984674B2 (el)
KR (2) KR101786444B1 (el)
CN (2) CN102655868A (el)
AU (2) AU2010340999B2 (el)
BR (2) BR112012013888A2 (el)
CA (2) CA2781576C (el)
CY (2) CY1118081T1 (el)
DE (1) DE202009017772U1 (el)
DK (2) DK2437747T3 (el)
ES (2) ES2594766T3 (el)
HR (2) HRP20161268T1 (el)
HU (2) HUE030460T2 (el)
LT (2) LT2437747T (el)
MX (2) MX2012006206A (el)
PL (2) PL2437747T3 (el)
PT (2) PT2437747T (el)
RS (2) RS55251B1 (el)
RU (2) RU2557897C2 (el)
SI (2) SI2437748T1 (el)
WO (2) WO2011082950A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189475A9 (en) * 2009-12-10 2017-07-06 Orthogen Ag Combination preparation comprising a cytokine antagonist and corticosteroid
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
CN104673749B (zh) * 2015-02-12 2017-10-20 江苏大学 一种粒细胞样髓源性抑制细胞来源exosomes及其应用
WO2017080669A1 (en) * 2015-11-13 2017-05-18 Orthogen Ag Pharmaceutical preparation effective in age-related disorders
AU2017313163B2 (en) * 2016-08-17 2019-01-03 Orthogen Ag Anti-ageing pharmaceutical preparation
CA3073137A1 (en) 2016-08-19 2018-02-22 Jeffrey S. Bartlett Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
WO2018056481A1 (ko) * 2016-09-23 2018-03-29 ㈜프로스테믹스 면역 억제 및 항염증성 조성물
AU2017371043B2 (en) 2016-12-07 2022-12-15 University Of Florida Research Foundation, Incorporated IL-1Ra cDNAs
CN108175759B (zh) * 2016-12-08 2021-03-19 暨南大学 一种抗肿瘤靶向给药系统及其制备方法与应用
EA038300B1 (ru) * 2017-04-18 2021-08-06 Юниверсити Оф Флорида Рисерч Фаундейшен, Инкорпорейтед Кднк il-1ra
CN108619114B (zh) * 2018-05-02 2020-08-11 东南大学 一种负载地塞米松的巨噬细胞源微囊泡及其制备方法和应用
CN109078171A (zh) * 2018-09-10 2018-12-25 因之彩生物科技（武汉）有限公司 一种外用组合物及其应用以及外用治疗剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2793159A (en) * 1955-03-09 1957-05-21 Upjohn Co Stable hydrocortisone solution
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
KR20040010739A (ko) 1996-02-09 2004-01-31 암젠 인코포레이티드 인터루킨-1 수용체 길항물질을 포함하는 융합 단백질 및 이를 포함하는 제약학적 조성물
WO1998035043A1 (en) * 1997-02-06 1998-08-13 Genetics Institute, Inc. Human sdf-5 protein and compositions
CH694074A5 (de) 1997-08-16 2004-07-15 Orthogen Gentechnologie Gmbh Verfahren zur Herstellung von therapeutisch wirksamen Proteinen.
DE19903876B4 (de) 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
DE10213780A1 (de) 2002-03-22 2003-11-27 Orthogen Ag Verfahren und Mittel zur Herstellung therapeutisch interessanter Blutzusammensetzungen
BRPI0512814A (pt) * 2004-07-01 2008-04-08 Univ Pittsburgh Of The Commmmo exosomas imunossupressivas
DE102004036840B4 (de) 2004-07-29 2012-04-19 Orthogen Ag Verfahren und Mittel zur Gewinnung von thrombocytenreichem Plasma
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
EP1906960A4 (en) 2005-07-11 2010-03-10 Astrazeneca Ab NEW COMBINATION 1
US7292185B2 (en) * 2005-10-04 2007-11-06 Csi Wireless Inc. Attitude determination exploiting geometry constraints
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
DE102006005016A1 (de) 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
US9724391B2 (en) 2017-08-08
JP5984674B2 (ja) 2016-09-06
AU2010340999B2 (en) 2014-08-14
CA2781223C (en) 2016-02-16
MX2012006206A (es) 2012-06-28
EP2437748B8 (de) 2016-10-19
HUE029979T2 (en) 2017-04-28
AU2010341000A1 (en) 2012-06-21
DK2437747T3 (en) 2016-10-24
CN102655868A (zh) 2012-09-05
DK2437748T5 (en) 2016-12-05
US20120237525A1 (en) 2012-09-20
AU2010340999A1 (en) 2012-06-21
PT2437747T (pt) 2016-10-18
RU2526161C2 (ru) 2014-08-20
US20190038719A1 (en) 2019-02-07
DE202009017772U1 (de) 2011-04-21
RS55217B1 (sr) 2017-02-28
KR20120107108A (ko) 2012-09-28
BR112012014066A2 (pt) 2017-04-04
EP2437747B8 (de) 2016-10-19
US20120237587A1 (en) 2012-09-20
US10537614B2 (en) 2020-01-21
BR112012013888A2 (pt) 2017-03-07
AU2010341000B2 (en) 2014-08-14
CA2781576C (en) 2016-02-09
CY1118081T1 (el) 2017-06-28
KR20120109542A (ko) 2012-10-08
HRP20161268T1 (hr) 2016-11-04
LT2437747T (lt) 2016-10-25
EP2437748B1 (de) 2016-08-31
JP2013513583A (ja) 2013-04-22
EP2437747B1 (de) 2016-08-31
EP2437748A1 (de) 2012-04-11
PT2437748T (pt) 2016-10-14
MX2012006430A (es) 2012-07-30
EP2437747A1 (de) 2012-04-11
HRP20161279T1 (hr) 2016-12-02
RU2557897C2 (ru) 2015-07-27
CN107096031A (zh) 2017-08-29
US8828946B2 (en) 2014-09-09
CA2781576A1 (en) 2011-07-14
DK2437748T3 (en) 2016-10-24
PL2437748T3 (pl) 2017-09-29
ES2594896T3 (es) 2016-12-23
KR101786444B1 (ko) 2017-10-18
WO2011082951A1 (de) 2011-07-14
SI2437747T1 (sl) 2016-12-30
JP2013513582A (ja) 2013-04-22
WO2011082950A1 (de) 2011-07-14
PL2437747T3 (pl) 2017-01-31
SI2437748T1 (sl) 2016-12-30
ES2594766T3 (es) 2016-12-22
CA2781223A1 (en) 2011-07-14
RU2012128877A (ru) 2014-01-20
LT2437748T (lt) 2016-11-10
RU2012128776A (ru) 2014-01-20
RS55251B1 (sr) 2017-02-28
US20130164303A2 (en) 2013-06-27
JP5907886B2 (ja) 2016-04-26
CN102652020A (zh) 2012-08-29
HUE030460T2 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1120866T1 (el) Παρεμποδιστες dna-pk
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
BR112013028779A2 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, método para tratar um paciente humano afligido com um distúrbio ou doença inflamatórios, e, uso de uma composição
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201001639A1 (ru) Композиции и способы их получения и применения
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
EA201171074A1 (ru) Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
CY1113146T1 (el) 11-φωσφο-στεροειδη παραγωγα ως τροποποιητες του υποδοχεα προγεστερονης
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CY1116802T1 (el) Ετεροκυκλικες ενωσεις
CY1118022T1 (el) Αναστολεις αποπτωσεως και χρησεις αυτων